Summary: Jazz Prescribed drugs will existing five abstracts at the 76th Once-a-year American Academy of Neurology Conference in Denver that aim on narcolepsy and idiopathic hypersomnia. Essential conclusions include things like a authentic-planet promises evaluation demonstrating greater hazards of comorbid situations with idiopathic hypersomnia and exploration on the advantages of reduced-sodium Xywav for slumber inertia and narcolepsy treatment method. The meeting will function both oral and poster displays.
Critical Takeaways:
- An oral presentation will depth outcomes from the Real-Environment Idiopathic Hypersomnia Total Overall health Design (RHYTHM) study, revealing higher odds of comorbid ailments, such as cardiovascular problems, in individuals with idiopathic hypersomnia compared to all those without having.
- Two posters will evaluate the affect of Xywav oral resolution on snooze inertia in people today with idiopathic hypersomnia, presenting facts from a phase 3 demo, demonstrating its efficacy as the very first small-sodium oxybate.
- A poster from the SEGUE examine will report final benefits on grownups with narcolepsy transitioning from higher-sodium Xyrem to small-sodium Xywav, displaying negligible dosage changes necessary for the switch.
- An additional poster will evaluation knowledge from 5 clinical research assessing the results of large-sodium oxybates on snooze quality and architecture in narcolepsy sufferers, indicating their performance in bettering slumber actions regardless of the significant-sodium articles.
Jazz Prescribed drugs plc will present a single oral presentation and 4 poster displays on narcolepsy and idiopathic hypersomnia at the 76th Once-a-year American Academy of Neurology Assembly, which will get spot April 13-18 in Denver.
A essential oral presentation will element benefits from a genuine-world statements analysis that shown the improved danger of comorbid ailments, these kinds of as stroke or cardiovascular illness, in persons dwelling with idiopathic hypersomnia compared to all those without the need of the issue.
Poster shows include the analysis of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral resolution on slumber inertia and slumber high-quality in people with idiopathic hypersomnia and narcolepsy, together with in-depth results from the SEGUE examine on transitioning narcolepsy people from superior-sodium to low-sodium oxybate treatment plans.
“Jazz’s presentations at the 2024 AAN Annual Meeting replicate our leadership in slumber and scarce epilepsies, as nicely as our dedication to acquiring therapies for debilitating, and frequently ignored, neurological conditions,” suggests Rob Iannone, MD, MSCE, executive vice president and worldwide head of study and progress of Jazz Prescribed drugs, in a launch. “We keep on being committed to growing our know-how of the client expertise, like the true-planet affect and usefulness of our solutions, in buy to attain our goal of reworking the life of people and their households.”
Highlights at the 2024 AAN Once-a-year Conference consist of:
- An oral presentation showcasing benefits from the Authentic-Entire world Idiopathic Hypersomnia Total Health Model (RHYTHM) review which, employing statements knowledge, in comparison the comorbid ailments of individuals identified with idiopathic hypersomnia with people experienced by people today devoid of idiopathic hypersomnia. Outcomes revealed that individuals with idiopathic hypersomnia seasoned greater odds of comorbid ailments across various clinical categories, together with cardiovascular problems, reaffirming the great importance of thinking of the patient’s entire scientific profile when evaluating treatment method possibilities for sufferers living with idiopathic hypersomnia.
- Two posters assessing the affect of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral remedy, the initially and only very low-sodium oxybate, on sleep inertia in persons living with idiopathic hypersomnia, which includes benefits from a phase 3 demo.
- A single poster reporting the closing outcomes from the SEGUE research of adults with narcolepsy transitioning from Xyrem (sodium oxybate) oral option, a substantial-sodium oxybate, to Xywav, demonstrating that contributors switched from significant-sodium to minimal-sodium oxybate with negligible adjustments to their dosing.
- A poster examining crucial knowledge from 5 medical reports evaluating the affect of all when- and twice-nightly significant-sodium oxybates on rest high quality, slumber architecture, and actions of disrupted nighttime snooze in narcolepsy. The evaluation identified that oxybate was successful in increasing measures of rest architecture and disrupted nighttime rest in patients with narcolepsy. Xyrem is indicated for the treatment of cataplexy and/or extreme daytime sleepiness in narcolepsy individuals.
The 2024 AAN Once-a-year Conference abstracts are out there below.
Photo 142024457 © Mary981 | Dreamstime.com
Leave a Reply